Digistain

14/08/2026

Excited to share our upcoming 𝗖𝗠𝗘-𝗮𝗰𝗰𝗿𝗲𝗱𝗶𝘁𝗲𝗱 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 in collaboration with Unilabs Middle East, where Hemmel Amrania PhD Breast Cancer Diagnostics will be presenting ’s landmark clinical validation data! 🩺

Traditional genomic recurrence testing can create severe bottlenecks due to cost and turnaround times. In this session, we’ll delve into how mid-infrared spectral phenotyping (FTIR) measures tumour aneuploidy directly from standard FFPE sections to deliver rapid, reliable recurrence risk profiling.

**𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀**
• 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻: 801-patient cohort with 12.7-year median follow-up.
• 𝗛𝗶𝗴𝗵 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆: ≥90% 10-year Negative Predictive Value (NPV).
• 𝗔𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗗𝗲-𝗲𝘀𝗰𝗮𝗹𝗮𝘁𝗶𝗼𝗻: Confidently identifies up to 49% of eligible HR+/HER2- early breast cancer patients who can safely avoid chemotherapy.
• 𝗥𝗮𝗽𝗶𝗱 𝗧𝘂𝗿𝗻𝗮𝗿𝗼𝘂𝗻𝗱: 10-minute analytical workflow integrating directly into standard pathology labs.

🔬 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗮𝘁𝘁𝗲𝗻𝗱: Oncologists, Pathologists, Breast Surgeons, and Oncology Professionals.

📜 𝗖𝗠𝗘 𝗔𝗰𝗰𝗿𝗲𝗱𝗶𝘁𝗲𝗱

Check out the post below to register and save your spot! 👇

https://lnkd.in/dvph-iRq

03/07/2026

Digistain continues to expand its international clinical development network, with meetings in China focused on promoting collaborative research.

Led by co-founder Chris Phillips and COO Sabrina Ali, the Digistain team had the pleasure of meeting with leading clinicians, researchers and pathology teams across major hospitals and innovation centres in Shanghai, including Zhongshan Hospital, Ruijin Hospital and the National Innovation Centre Par Excellence.

These meetings explored the growing role of our tumour intelligence platform in supporting future clinical research, evidence generation and faster, more accessible approaches to cancer risk stratification.

China is one of the world's most dynamic hubs for clinical innovation, with data-rich hospital systems, strong academic networks and real momentum around precision oncology. For Digistain, this visit represented an important opportunity to explore how our technology can support robust clinical validation across broader patient populations and additional cancer pathways.

At Zhongshan Hospital, Professor Chris Phillips met with Professor Ji, Consultant Pathologist and Head of the Pathology Department, to discuss pathology workflows and future collaboration. At Ruijin Hospital, conversations turned to clinical development and how Digistain could work alongside leading oncology teams to generate meaningful evidence in high-need cancer areas.

This visit marks another step in Digistain's growing global presence, as we build relationships with world-class clinical and academic partners across the UK, Europe, Asia, Africa and beyond.

We are grateful to everyone who took the time to meet with the Digistain team, and look forward to continuing these conversations as we work to bring faster, more affordable risk stratification to patients worldwide.

01/04/2026

Digistain at South Summit Brazil 2026 | EUREKA Investment Readiness Program

We were honoured to attend South Summit Brazil 2026 as part of the EUREKA Investment Readiness Programme, where we were provided with a valuable platform to engage with investors, partners, and the wider innovation ecosystem.

As we progress a bridge round to support our next phase of growth ahead of a planned Series A, the event created meaningful opportunities to connect with investors aligned to our vision of enabling more equitable and sustainable cancer care.

With over 200,000 new breast cancer diagnoses annually, Latin America represents an important and rapidly evolving market, where improving access to cost-effective risk stratification has the potential to deliver significant clinical and system-level impact. As we continue to expand our presence in the region through our growing distributor network in Brazil, the event also facilitated a number of important commercial discussions, supporting the acceleration of our regional commercial strategy.

Thank you to the EUREKA Network for supporting our participation.

We look forward to building on these conversations and continuing to drive forward our global expansion.

18/03/2026

Digistain Engages with Global Health Leaders at Thailand BOI Roundtable

Digistain was pleased to be represented at the Thailand Board of Investment roundtable hosted at the Thai Embassy in London.

The evening brought together leaders from healthcare, investment, and policy, including the Director of the Thailand Board of Investment and the Thai Ambassador to the UK, to discuss opportunities for collaboration and innovation.

As global interest in advanced oncology solutions continues to grow, conversations like these play an important role in shaping partnerships that can improve patient outcomes across regions.

We look forward to continuing our engagement in Southeast Asia and exploring opportunities to bring innovative solutions to new markets.

04/03/2026

Digistain announces partnership with Rhythm Biosciences to distribute geneType® across Southeast Asia

We are delighted to announce that Digistain has secured the rights to distribute geneType across Southeast Asia.

Developed by publicly listed Australian company Rhythm Biosciences, geneType is a next-generation risk assessment platform which predicts an individual’s likelihood of developing various cancers and chronic diseases. By integrating genetic data with clinical factors and family history, it allows for a more comprehensive view of disease susceptibility.

Through our established supply chain networks and growing commercial footprint in the region, we aim to accelerate availability of geneType's genetic test portfolio to healthcare providers and patients across Southeast Asia, broadening access to innovative diagnostics where it's needed most.

This partnership marks an important strategic milestone for both organisations, deepening our mutual commitment to personalised, equitable healthcare. With extensive clinical networks already in place, we are uniquely positioned to bring this technology to patients at scale.

Together our complementary strengths and shared vision bring us one step closer to making precision healthcare accessible to all.

To read more about the partnership, you can access the full press release here: https://rhythmbio.com/investor-center/

We appreciate your interest in Rhythm Biosciences and invite you to explore how we’re working to create long-term value for patients and shareholders alike.

18/02/2026

We’re delighted to share that we’ve been selected as one of just 27 companies by the EUREKA Investment Readiness Network to participate in a mission to South Summit Brazil, taking place from 25 to 27 March.

As part of a competitive assessment process, companies were evaluated on their ability to address a clear unmet clinical need, demonstrate strong market alignment and real-world scalability to translate innovation into sustained commercial impact.

This recognition marks an important milestone for Digistain, reinforcing confidence in our technology’s potential to deliver meaningful and accessible change for breast cancer patients worldwide.

South Summit Brazil is one of Latin America’s leading innovation and investment events, and we’re especially pleased to share that we have also been selected as one of 12 companies to participate in a dedicated pitching session, highlighting our investability and regional expansion potential.

Alongside the pitching session, we will be showcasing Digistain at our exhibition booth, where we look forward to sharing more about the technology and our plans for expansion across Latin America.

If you’re attending South Summit Brazil, we would love to connect and we hope to see you there!

14/11/2025

Digistain Sees Rapid Clinical Uptake across South Africa

We are proud to announce that following the official launch of Digistain in South Africa last month, the technology has already been successfully integrated into routine clinical practice by local oncologists.

Why this matters: remains the most common cancer among South African women, accounting for about 22.6% of all female cancers and 16% of cancer related deaths in women. In 2022 alone, more than 14,700 new breast cancer cases were identified in South Africa.

Through informed choices, our early adopters are already seeing the impact of faster decision making and improved alignment of patient care, helping make a meaningful difference for patients where they need it most.

Thank you to all our clinical partners, teams and advocates who are helping bring this into practice across South Africa. We look forward to building on this progress as we continue to support all women living with breast cancer in this region.